Retrospective Study
Copyright ©The Author(s) 2015.
World J Radiol. Dec 28, 2015; 7(12): 494-500
Published online Dec 28, 2015. doi: 10.4329/wjr.v7.i12.494
Figure 2
Figure 2 Cumulative incidence of testosterone recovery to normal levels (A) and supracastrate levels (B) according to duration of gonadotropin-releasing hormone agonist therapy. Significance (P < 0.05) was determined according to a Log-Rank test.